Non-invasive prenatal testing (NIPT) is a genomic technology used to predict the chance of a foetus having a genetic condition. Despite the immediacy of this technology’s integration into clinical practice, there is a dearth of evidence outlining how both patients and professionals experience NIPT on the ground. In this article, we draw upon our collective empirical research—specifically on earlier screening technologies (BKR), Down syndrome screening (GT), genetic screening/testing (JL) and NIPT (HS)—to outline the most pressing and often controversial issues which, we argue, remain unresolved and vital to consider regarding NIPT. We begin with a brief introduction to NIPT as a prenatal technology and the bodies of literature which unpack its ‘social life’. In what follows, BKR discusses NIPT within the context of her research on ‘the tentative pregnancy’ and diagnostic testing in the USA. In the following sections, GT, HS and JL identify different, but related, concerns with respect to NIPT, particularly around routinisation, commercialisation, choice, abortion, and configurations of disability and ‘normalcy’.

无创产前检查（NIPT）是一种基因组技术，用于预测胎儿患有遗传病的机会。尽管该技术已被立即集成到临床实践中，但仍缺乏足够的证据来概述患者和专业人员在现场如何体验NIPT。在本文中，我们将利用我们的集体经验研究（特别是早期筛查技术（BKR），唐氏综合症筛查（GT），基因筛查/测试（JL）和NIPT（HS））概述最紧迫且最有争议的问题我们认为，对于NIPT，这些问题仍未解决且至关重要。我们首先简要介绍NIPT作为一种产前技术，以及介绍其“社会生活”的文学作品。在下面，BKR在美国对“暂定怀孕”和诊断测试的研究背景下讨论了NIPT。在以下各节中，GT，HS和JL在NIPT方面确定了不同但相关的关注点，特别是在常规化，商业化，选择，堕胎以及残障和“正常”状况方面。